PRMT1 and neoplasm: In CRC, methylation of R198/200 in the extracellular domain of EGFR by PRMT1 enhanced receptor dimerization and cell proliferation, resulting in tumor cell resistance to the anti-EGFR monoclonal antibody cetuximab [26].